{"schema_version":"1","generated_at":"2026-11-11T01:29:45.222Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sean-warsch","json_url":"https://www.findmykol.com/kol/sean-warsch/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sean-warsch","name":"Sean Warsch","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Asheville","state":"NC","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1750608246","openalex":"A5006644731"},"summary":"Sean Warsch is an Oncology physician. OpenAlex indexes 20 publications with 337 citations (h-index 9).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":20,"cited_by_count":337,"h_index":9,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":68,"program_years":{"first":2021,"last":null},"rows_total":150,"shown":3,"withheld":147,"rows":[{"payer":"SpringWorks Therapeutics, Inc.","program_year":2025,"amount_usd":1765.69,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750608246"},{"payer":"Caris MPI, Inc.","program_year":2025,"amount_usd":1167.48,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750608246"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2025,"amount_usd":317.36,"payment_count":13,"source_url":"https://openpaymentsdata.cms.gov/search?query=1750608246"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1750608246","source":"payments"},"prescribing":{"data_year":2024,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":59.2,"classes_total":16,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":24.4,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":25},{"class":"Platinum-based Drug","setting":"administered","share_pct":19.6,"drugs":[{"name":"Oxaliplatin","share_pct":97.2},{"name":"Cisplatin","share_pct":1.6},{"name":"Carboplatin","share_pct":1.2}],"max_beneficiaries":14}]},{"area":"Metabolism & gastrointestinal","share_pct":24.1,"classes_total":6,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":20.7,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":42},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":2.4,"drugs":[{"name":"Palonosetron hcl","share_pct":79.6},{"name":"Ondansetron hydrochloride","share_pct":16.7},{"name":"Ondansetron Odt","share_pct":3.7}],"max_beneficiaries":58}]},{"area":"Musculoskeletal","share_pct":6.1,"classes_total":3,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":5.9,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":29},{"class":"Bisphosphonate","setting":"administered","share_pct":0.2,"drugs":[{"name":"Zoledronic acid","share_pct":100}],"max_beneficiaries":24}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":99.8,"facility_pct":0.2},"source":"medicare"},"publications":{"total":20,"shown":5,"withheld":15,"matched_by":"OpenAlex author record","recent":[{"title":"Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab","year":2017,"journal":"Clinical Lung Cancer","source_url":"https://doi.org/10.1016/j.cllc.2017.12.007","status":"verified"},{"title":"Patient with Typical Carcinoid Initially Diagnosed as High-Grade Neuroendocrine Carcinoma","year":2017,"journal":"Lung Cancer Management","source_url":"https://doi.org/10.2217/lmt-2017-0010","status":"verified"},{"title":"P3.02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab","year":2017,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2016.11.1877","status":"verified"},{"title":"P2.07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab","year":2017,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2017.11.096","status":"verified"},{"title":"PS01.38: Patient with a Typical Carcinoid Initially Diagnosed as High-Grade Neuroendocrine Carcinoma","year":2016,"journal":"Journal of Thoracic Oncology","source_url":"https://doi.org/10.1016/j.jtho.2016.09.073","status":"verified"}],"source":"works"},"contact":{"address_1":"551 BREVARD RD","city":"Asheville","state":"NC","zip":"288062316","phone":"828-212-7021","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1750608246","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":147,"publications":15}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2022-12-29","provider_certified":"2022-12-29","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}